Quick Answer
Anika Therapeutics, Inc. reported Total Revenue of $112.82 million for fiscal year 2025.
Anika Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $112.82M -5.9% |
$119.91M -0.7% |
$120.79M +6.1% |
$113.83M -23.0% |
$147.79M +13.3% |
$130.46M +13.8% |
| Revenue (ASC 606) | $112.82M -5.9% |
$119.91M -0.7% |
$120.79M +6.1% |
$113.83M -23.0% |
$147.79M +13.3% |
$130.46M +13.8% |
| Net Income | -$10.88M +80.7% |
-$56.38M +31.8% |
-$82.67M -456.3% |
-$14.86M -459.4% |
$4.13M +117.2% |
-$23.98M -188.2% |
| Diluted EPS | -$0.76 +80.2% |
-$3.83 +32.1% |
-$5.64 -452.9% |
-$1.02 -464.3% |
$0.28 +116.6% |
-$1.69 -189.4% |
| Total Assets | $190.27M -6.2% |
$202.74M -25.1% |
$270.63M -22.5% |
$349.13M +0.5% |
$347.54M -4.9% |
$365.61M +10.6% |
| Cash and Equivalents | $57.48M +3.3% |
$55.63M -19.1% |
$68.74M -20.4% |
$86.33M -8.5% |
$94.39M -1.5% |
$95.82M -39.1% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $143.47M -6.8% |
$153.99M -27.5% |
$212.26M -25.7% |
$285.56M -0.5% |
$287.08M +5.4% |
$272.40M -5.5% |
| R&D Expense | $25.77M +0.9% |
$25.54M +17.4% |
$21.76M +18.8% |
$18.32M -33.0% |
$27.33M +16.6% |
$23.43M +40.6% |
| Operating Income | -$11.05M -116.6% |
-$5.10M -704.4% |
$844.0K -77.0% |
$3.67M +40.3% |
$2.62M +109.2% |
-$28.32M -182.7% |
| Gross Profit | $63.81M -16.0% |
$76.00M -7.9% |
$82.53M +12.7% |
$73.22M -11.7% |
$82.94M +20.2% |
$69.03M -19.6% |
| Shares Outstanding | 13.89M -3.7% |
14.42M -1.7% |
14.66M +0.2% |
14.62M +1.3% |
14.44M +0.8% |
14.33M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $27.82M | -5.9% | -1.4% |
| Revenue (ASC 606) | September 30, 2025 | $27.82M | -5.9% | -1.4% |
| Net Income | September 30, 2025 | -$2.33M | +92.2% | +41.3% |
| Diluted EPS | September 30, 2025 | -$0.16 | +92.1% | +42.9% |
| Total Assets | September 30, 2025 | $189.44M | -18.1% | +0.9% |
| Cash and Equivalents | September 30, 2025 | $57.99M | -7.0% | +9.1% |
| Long-Term Debt | September 30, 2020 | $25.00M | — | -50.0% |
| Stockholders Equity | September 30, 2025 | $146.81M | -18.4% | -0.6% |
| R&D Expense | September 30, 2025 | $6.95M | +16.8% | +10.0% |
| Operating Income | September 30, 2025 | -$3.23M | -3891.4% | +22.7% |
| Gross Profit | September 30, 2025 | $15.58M | -19.7% | +8.5% |
| Shares Outstanding | September 30, 2025 | 14.42M | -1.9% | +0.0% |
- Anika Therapeutics, Inc. reported Total Revenue of $112.82 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -5.9% in Total Revenue compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Revenue (ASC 606) of $112.82 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -5.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Net Income of -$10.88 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed an increase of +80.7% in Net Income compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Diluted EPS of $0.76 per share (loss) for fiscal year 2025.
- Anika Therapeutics, Inc. showed an increase of +80.2% in Diluted EPS compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Total Assets of $190.27 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -6.2% in Total Assets compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Cash and Equivalents of $57.48 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed an increase of +3.3% in Cash and Equivalents compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Long-Term Debt of $8.00 million for fiscal year 2012.
- Anika Therapeutics, Inc. showed a decrease of -16.7% in Long-Term Debt compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Stockholders Equity of $143.47 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -6.8% in Stockholders Equity compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported R&D Expense of $25.77 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed an increase of +0.9% in R&D Expense compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Operating Income of -$11.05 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -116.6% in Operating Income compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Gross Profit of $63.81 million for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -16.0% in Gross Profit compared to the prior fiscal year.
- Anika Therapeutics, Inc. reported Shares Outstanding of 13.89 million shares for fiscal year 2025.
- Anika Therapeutics, Inc. showed a decrease of -3.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: